HMGB1 is implicated in the development of non-alcoholic fatty liver Disease (NAFLD) by insulin receptor downstream effectors (Arrigo et al., 2013; Wang et al., 2015; Giacobbe et al., 2016). This evidence concerns the gene HMGB1 and metabolic dysfunction-associated steatotic liver disease.